Compare Ascendis Pharma A/S (ASND) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs KKR & Co Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while KKR & Co Inc trades at $96.68 (market cap $87.04B). The key difference: KKR & Co Inc is far larger — about 4.9× Ascendis Pharma A/S's market cap, and KKR & Co Inc pays a 0.77% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KKR | |
|---|---|---|
Market Cap | $17.74B | $87.04B |
Sector | Health | Financials |
52-Week High | $277.18 | $152.16 |
52-Week Low | $163.32 | $83.88 |
Enterprise Value | $18.11B | $12.56B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KKR trades at $96.94, up 0.7% today, with a bullish technical outlook supported by moving averages and near-term resistance at $97. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic acquisitions like the $4.2 billion EDF power solutions deal and a $1.3 billion renewable energy platform in South Korea. Strong analyst sentiment includes 24 buy ratings and a consensus price target of $127.71, indicating significant upside potential.
The outlook for KKR is positive, driven by robust monetization activity, strategic growth initiatives, and a favorable analyst consensus. Key risks include volatile cash flows from operations, high leverage with long-term debt of $49.91 billion, and dependence on private market conditions. Investors should weigh the growth opportunities against these financial and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
